beta
Trial Radar AI
Clinical Trial NCT03667417 (GENEPSO) for Breast Cancers, Ovarian Cancers is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation (GENEPSO) 5,000

Recruiting
Clinical Trial NCT03667417 (GENEPSO) is an observational study for Breast Cancers, Ovarian Cancers that is recruiting. It started on 15 October 1999 with plans to enroll 5,000 participants. Led by Institut Paoli-Calmettes, it is expected to complete by 15 October 2028. The latest data from ClinicalTrials.gov was last updated on 1 July 2020.
Brief Summary
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
Detailed Description
Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers
Official Title

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

Conditions
Breast CancersOvarian Cancers
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • GENEPSO
  • GENEPSO-IPC 2018-031
NCT ID Number
NCT03667417
Start Date (Actual)
1999-10-15
Last Update Posted
2020-07-01
Completion Date (Estimated)
2028-10-15
Enrollment (Estimated)
5,000
Study Type
Observational
Status
Recruiting
Keywords
BRCA gene mutation
Arms / Interventions
Participant Group/ArmIntervention/Treatment
subjects carrying a BRCA gene mutation
subjects carrying a BRCA gene mutation
Questionnaires
standardized data collection and 10-year prospective follow-up
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Incidence of breast and / or ovarian cancer during subject lifetime
risk that a subject with a mutation develops breast and / or ovarian cancer during his lifetime, assessed by epidemiologic questionnaires (carcinologic events).
10 years
Participation Assistant
Eligibility Criteria

  1. Woman or man, with or without cancer, carrying a deleterious BRCA1/BRCA2 mutation, aged 18 years and over.

    1. Woman with or without breast cancer or ovarian cancer at baseline.
    2. Man with or without breast cancer at baseline.

  2. Signed consent to participation

  3. Affiliation to a social security regimen, or beneficiary of such a regimen.

  4. A person of legal age subject to a legal protection measure, or unable to express consent.

  5. Impossibility to submit to the follow-up of the test for geographical, social or psychological reasons

Institut Paoli-Calmettes logoInstitut Paoli-Calmettes
UNICANCER - Le Groupe génétique et cancer (GGC) logoUNICANCER - Le Groupe génétique et cancer (GGC)
Study Central Contact
Contact: Dominique GENRE, MD, 33 491 22 37 78, [email protected]
Contact: Margot BERLINE, MSc, MBA, 33 491 22 33 14, [email protected]
1 Study Locations in 1 Countries
Institut Paoli-Calmettes, Marseille, 13009, France
Catherine NOGUES, MD, Contact, 334 91 223395, [email protected]
Catherine NOGUES, MD, Principal Investigator
Recruiting